SemBioSys Genetics Inc.

Presenter: James Szarko, Director, President and CEO

Company Information

Company Type: Pharmaceuticals

Development Stage: Public

Company Profile

Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys' seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

Presenter Bio

James Szarko joined SemBioSys in September 2004 as Chief Financial Officer. He has 23 years of business and leadership experience in various roles as a Chartered Accountant, management consultant and an executive. Prior to joining SemBioSys, Mr. Szarko provided consulting and financial management services to early stage growth companies primarily in the technology area. He also held a senior position with a large public company. Mr. Szarko began his career at PricewaterhouseCoopers LLP where he advanced to the position of senior manager which included a three year international assignment. Mr. Szarko is currently a member of the Advancement Committee to the Board of Governors of the University of Lethbridge and has served on various boards and committees in both the profit and non-profit sectors.

Contact

SemBioSys Genetics Inc.
110, 2985 - 23rd Avenue N.E.
Calgary
AB , Canada
T1Y 7L3

ph: 403-250-5424
fx: 403-250-3886

www.sembiosys.com
szarkoj@sembiosys.ca